In Vitro and In Vivo Chemotherapeutic Activity of Rifabutin (LM 427) on Mycobacterium avium-intracellulare Complex by SAKURAI, Nobuo & KUZE, Fumiyuki
Title In Vitro and In Vivo Chemotherapeutic Activity of Rifabutin(LM 427) on Mycobacterium avium-intracellulare Complex
Author(s)SAKURAI, Nobuo; KUZE, Fumiyuki
Citation京都大学結核胸部疾患研究所紀要 (1987), 20(1/2): 50-60
Issue Date1987-08-31
URL http://hdl.handle.net/2433/52119
Right
Type Departmental Bulletin Paper
Textversionpublisher
Kyoto University
In Vitro and In Vivo Chemotherapeutic Activity of Rifabutin
(LM 427) on Mycobacterium avium-intracellulare Complex
Nobuo SAKURAI and Fumiyuki KUZE
Fz"rst Department of Medicz"ne, Chest Dz"sease Research Instz"tute,
Kyoto Unzversz"ty, Kyoto, Japan
(Received, March 15, 1987)
SUMMARY
In vitro chemotherapeutic activity of rifabutin against Mycobacterium avium (-intracellulare)
complex was studied with 20 Japanese disease-associated strains. In vitro superiority of rifabutin
to rifampin (RMP) was clearly demonstrated in three different kinds of media. A tendency of
parallelism in susceptibility of individual strains between rifabutin and RMP was confirmed in
a correlation analysis of MICs of the both drugs in Kirchner's liquid medium, but not in a
modified Dubos Tween® albumin liquid medium.
The murine experimental infection with a mouse-virulent strain 31F093T was used to evaluate
in vivo activity of rifabutin in comparison with that of RMP with 3 treatment dosages. Rifabu-
tin suppressed moderately the total number of grossly visible lung disease. In the evaluations of
consecutive viable bacilli in the organs of mice, neither superiority of rifabutin to RMP, no dose
responses of the both drugs were demonstrated.
This challenging results could be mostly due to a high resistance of31F093T strain to rifabutin.
INTRODUCTION
Pulmonary and disseminated disease caused by Mycobacterium avium complex is of growing
importance due to its high frequency in complicating locally as well as systemically compromi-
sed hosts (1-3). The organism is resistant to most of the available antimycobacterial drugs, and
even chemotherapeutic trials of various multidrug regimens have been far from satisfactory
(4-6).
Urgent need for better chemotherapeutic agents prompted us to evaluate especially in vivo
activity of rifabutin (a spiro-piperidyl rifamycin, LM 427), which has been reported to have high
in vitro activity against mycobacteria (7-12).
The present study was planned to assess, first, the in vitro activity of the drug against M.
avium complex strains isolated in our laboratory, and then to evaluate in vivo activity in our
experimental murine infection model (13-15).
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METHODS
Rifabutin
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Rifabutin (in pure powder) was obtained from Dr. A. Sanfilippo and Dr. C. Della Bruna of
Microbiological Department, Farmitalia Carlo Erba C., Italy.
In vitro study
Mycobacterium avium complex strains used in the present in vitro study were all individually
disease-associated, and the isolates before any treatment. Twenty strains were selected because
of showing high purity of smooth thin-transparent colony form (16). The strains had been stored
in a refrigerator at 4°C on 1% Ogawa medium until the experiments. Before the assessment of
in vitro activity, their colony types were observed on cornmeal agar media with 1.5% glycerol,
and the purification to smooth thin-transparent colony type was done by the method described
beforehand (16). Inoculums were made by transferring to a modified Dubos Tween® albumin
liquid medium (DTA), and the 2 week-old cultures were diluted with sterile normal saline so as
to inoculate ca. 0.01 mg (0.05 ml) of bacilli into liquid media and also ca. 0.01 mg (0.1 ml) on
Ogawa medium, respectively, with the aid of a comparable barium sulfate solution
Three kinds of medium, the modified Dubos Tween® albumin liquid medium with 0.05%
Tween® 80 (DTA), Kirchner's liquid medium with 10% bovine serum (KB), and 1% Ogawa
solid medium, were used for determination of MICs of rifabutin. The MICs of rifabutin were
compared simultaneously with those of rifampin (RMP), Kanamycin (KM), and cefazolin (CEZ)
(17) in the liquid media; with only RMP on 1% Ogawa medium. Rifabutin and RMP were
initially disolved in methanol (98%) and DMSO, respectively. In the liquid media, serially dou-
bly diluted concentrations of the drugs (2.0 ml) were tested for determination of MICs, while the
growths were observed on the Ogawa media containing 10,25, 50, 100, 150, 200, 250,300, and 400
,ug/ml of the drugs. The MICs were determined after 2 wks incubation in the liquid media,
4 wks in Ogawa medium.
In vivo study
The mouse-virulent strain M. avium complex 31F093T (No.6 in table 1) (15) was used to
infect conventional ddY male mice weighing 20 to 25 g. The inoculum of the strain 31F093T
was produced in the modified Dubos Tween® albumin liquid medium, and 0.2 ml of the 2-wk-old
culture was used for intravenous injection into a tail vein in each mouse. Appropriate dilutions
of the inoculum were inoculated onto Ogawa media to determine the number of colony forming
units. The strain 31F093T was also included in the present in vitro study, and revealed to be
partially resistant to 50,ug/ml of rifabutin on Ogawa medium (table 1).
Both rifabutin and RMP were orally administered of 2.0 ml of the drug emulsions, directly
into the stomach through a small metal tube attached to a 1-ml syringe. Treatment dosages in
milligrams per kilogram per day in both drugs were 25, 12.5, and 6.25. Treatment was begun
immediately after infection, and was continued through 12 wk of infection, 6 days per week.
For evaluation of the effect of the chemotherapeutic regimens, 5 mice in each treatment group
were killed at 1 wk and 3 wks of infection, and thereafter at 3 wks interval for observation of
gross lesions, organ weights, and for counting viable bacilli in organs. With 3 of the 5 mice
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killed, bacilli
weighed, then
homogenizer.
in organs were enumerated. Respective organs of 3 mice were combined and
ten fold organ homogenates with 2.0% NaOH were obtained, using an electric
Counting of viable bacilli in organs was done as previously described (15).
RESULTS
In vz'tro study
Cumulative percentages of the 20 strains of M. avz'um complex inhibited by rifabutin in
both DTA and KB were illustrated in figure 1 and 2, respectively. In DTA, rifabutin at con-
centration of 0.1 fl-g/ml inhibited all the 20 strains, whereas the same concentration of RMP in.
hibited only 4 strains. CEZ and KM were slightly less active than RMP. The concentrations
which inhibited 80% of the strains tested, were 0.05 fl-g/ml in rifabutin and 1.56 fl-g/ml in RMP.
Superiority of rifabutin to RMP was clearly demonstrated in DTA (figure 1). Although the
absence of Tween® 80 and possibly the addition of bovine serum lowered considerably the activities
of both rifabutin and RMP, the superiority of rifabutin to RMP was again demonstrated in
KB. Rifabutin inhibited all the 20 strains at the concentration of 6.25 g/ml, and only 20% of
the strains were inhibited at the same concentration of RMP (figure 2). Ten strains were rando-
mly selected from the 20 strains, and the activity of rifabutin was studied on Ogawa medium
(Table 1). The potent activity of rifabutin was also demonstrated on this medium. Rifabutin
inhibited 9 out of the 10 strains at the concentration of 50 fl-g/ml, while 9 strains were resistant
to 50 fl-g/ml of RMP. There existed two groups of strains, five strains demonstrated high degree
of resistance to RMP, MICs of which were more than 400 fl-g/ml, while the remains showed lower
resistance to RMP. Four strains of the latter were susceptible to less than 10 fl-g/ml of rifabu-
tin, while the former were all resistant to 25 ",g/ml of rifabutin.
Cumulative percentage of 20 strains of M. avz'um complex inhibited by LM
427, RMP, KM, and CEZ in a modified Dubas Tween® albumin medium.
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Fig. 2. Cumulative percentage of 20 strains of M. avium complex inhibited by LM
427, RMP, KM, and CEZ in Kirchner's medium.
Table 1 In Vziro Susceptibility of Rifabutin (LM427) and RMP on Ogawa Medium
Four weeks after inoculation, Inoculum 1O-3mg
Drug concentrations (fJ-g/ml)
Strain
10 25 50 100 150 200 250 300 400 C
1 RMP ++ ++ ++ tttt
LM 427 tttt
2 RMP
-Ittt +++ + -Ittt
LM 427 tttt
3 RMP +tt ++ + + tttt
LM 427 tttt
4 RMP -Ittt -Ittt tttt tttt +tt +++ +++ ++ + tttt
LM 427 ++ + tttt
5 RMP tttt tttt +tt +tt +tt ++ ++ + + tttt
LM 427 ++ + tttt
6* RMP -Ittt tttt tttt tttt tttt tttt +++ ++ + tttt
LM 427 +tt ++ + tttt
7 RMP tttt tttt tttt tttt tttt +tt +++ + + tttt
LM 427 +tt + tttt
8 RMP +tt +tt +tt +tt +tt ++ ++ + + tttt
LM 427 ++ + tttt
9 RMP +tt + tttt
LM 427 tttt
10 RMP +tt +tt ++ ++ + tttt
LM 427 ++ tttt
Definition of abbreviations: - =no growth; + =1 to 200 colonies; ++=200 to 500 colonies; +tt=500 to
2,000 colonies; tttt =more than 2, 000 colonies. The growths designated as +++ and tttt are confluent abun-
dant growths. The number of colonies are the estimates by experimental data.; C = control medium.
* 31T093T strain
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Fig. 3. Average lung weights of mice infected with M. avium complex 31F093 T. Treatment
with LM 427 demonstrated moderate suppressions of lung weights in all 3 treatment
dosages. Each point represents the average value for 5 mice except indicated by a
number in parentheses.
In vzvo study
In view of a high in vitro susceptibility of M. avium complex to rifabutin, a trial of ex-
perimental chemotherapy with our murine model (13, 15) was warranted to evaluate in vivo
therapeutic efficacies of rifabutin in comparison with those of RMP.
Oral treatment with all three treatment dosages of rifabutin demonstrated moderate suppressi-
ons of lung weights during the entire period of experiment (figure 3). Nodose responses of ri-
fabutin were clearly discernible, although the highest dosage (25 mg/kg) appeared only the re-
gimen which showed unequivocal suppresion of lung weights in RMP.
Highest dosages of both rifabutin and RMP (25 mg/kg) lowered considerably spleen weights
(figure 4). With two lower dosages of both drugs, no dose responses were demonstrated, although
slight to moderate suppressions of spleen weights were undoubtedly discernible around 9 wks of
infection.
Total number of mice which showed macroscopic lung lesions (+, tt, -Itt, #tt in table 2)
Table 2 Chemotherapeutic Effects of Rifabutin (LM427) and Rifampin on Mycobacterium avium complex
<:Infection in Mice Macroscopic Lesion S
tV
Lapse of Untreated LM427 25mg/kg LM427 12.5mg/kg LM427 6.25mg/kg 0ZTime after
- -Zung --liver .. Kidney Lung Lzver Kit/my- ----Lung Lzver Kzdney· Lung Liver .. Kz'dney ?Infection (4 to 5 mice)* (5 mice) (4 to 5 mice) (5 mice) .......
tV
tl+ t + + + + s:1 week 0/4 0/4 0/5 0/5 0/5 0/5 0/5 0/5 III"1I")
::s-
....
3 weeks ++ ill +t 2/5 + 0/5 ++ - 0/5 2/5 1/5 0/5
'..0
1t /5 0/5 00++ + +t + tl+ + 'I
tl+ ill +t ++ tl+ ill +t tl+ ill ++ + +t >6 weeks 3/5 1/5 3/5 4/5 4/5 1/5 1/5 2/5 ('")tl+ ill + +t +t tl+ ++ ill
.....
~:
.....
'<:
9 weeks tl+ ill ill 5/5 2/5 tl+ tl+ ill 2/5 1/5 + +t ill 4/5 2/5 ill + tl+ 5/5 1/5 0tl+ ill + ill +t +t ill +t -.~
tttt tl+ ill + ill +t +++ + ill +t ++ ill ~12 weeks 4/5 2/5 2/5 2/5 4/5 0/5 5/5 2/5 cr"tl+ ill tl+ tl+ ++ ill ill ~.....S'
0
Lapse of RMP 12.5mg/kg ='RMP 25mg/kg RMP 6.25mg/kg ~Time after
Infection
Lung------Ziver--- Kz'dn-ey- Lung Lzver Kidney Lung Liver Kidney >:l(4 to 5 mice) (5 miceL. (5 mice) N...
~
;i
1 week 0/4 0/4 + +t 0/5 0/5 + 0/5 0/5 (")+ + 0S
'0
~ + + + + +t +tt ++ (;'3 weeks 0/5 0/5 1/5 2/5 0/5 2/5 ><+ - ++ + +t
6 weeks +tt +tt 2/5 0/5 +tt +t ++ 2/5 2/5 ++ ++ +tt 1/5 1/5+ ill tl+ ++ +
9 weeks ++ ill tl+ 2/5 1/5 tl+ tl+ ill 4/5 2/5 +tt +tt tl+ 4/5 2/5tl+ +t tl+ ill tl+ ill
12 weeks tl+ tl+ +t 3/4 2/4 ++ tl+ +t 4/5 1/5 ill tl+ tl+ 4/5 1/5tttt +tt +tt tl+ ill
* Nurn ber of mice sacrificed at each interval.
t Number of mice with gross lesions. CJl
t grades of lung lesion: - =no gross lesion; + = scattered small nodules; +t=many small nodules; ill=innumerable small nodules; =innumerable small CJl
nodules with scattered big nodules.
RMP
25mg /kg
12. 5 lilli/kg
6.25mg/kg
0-----0 LM 427
0-----0 LM 427
0-----0 LM 427
e-------e control
....--...... RMP 25II1II Ikg
...-._--.... RMP 12. 5lilli/kg
..... ----.. RMP 6. 2511111/kg
______ control
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Fig. 4· Average spleen weights of mice infected with M. avium complex 31F093T. Highest
dosages of both LM 427 and RMP lowered considerably spleen weights. Each point
represents the average value for 5 mice.
during the entire period of experimentation were 23 out of 24 (96%) in the untreated mice, while
70% (52/74) and 79% (58/73) of the mice treated with rifabutin and RMP, respectively, demon-
strated grossly visible lung diseases (table 2). Concerning advanced diseases (++1- to fttt in table 2),
rifabutin allowed them to develop in 31% (23/74) of mice, while 42% (31/73) demonstrated
advanced diseases in the mice treated with RMP. The percentage in untreated mice was 67%
(16/24) (Table 2).
The above scores of both the total gross diseases and advanced diseases confirmed therapeu-
tic efficacy of rifabutin (P < 0.05, P < 0.01, x2-test), although the drug was not potent enough to
cure the diseases in single usage.
Total number of gross disease as well as advanced disease appeared lower in the mice treated
with RMP than in untreated mice. The differences were, however, not significant in total gross
diseases, but significant (P < 0.05) in advanced diseases. No dose responses of both rifabutin
and RMP were demonstrated.
Slight reductions of the viable counts of mycobacteria in lung were observed in mice
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Fig. 5. Average viable counts of mycobacteria from lungs and spleens of mice infected with
M. avium complex 31F093T. Each point represents the average value for 3 mice.
Slight reductions of the viable counts of mycobacteria were observed in mice treated
with both LM427 and RMP.
treated with both rifabutin and RMP, while the trend was not demonstrated in the counts of
spleens (figure 5). Nodose responses were discernible in both drugs. It is worthy to note
that rifabutin and RMP showed almost the same in vivo activity in our murine model in the
evaluations of consecutive viable bacilli in the organs.
DISCUSSION
Rifabutin has already been reported to have high in vitro activity against mycobacteria (7-12).
Preliminary report showed the drug to be comparable or even slightly better than RMP in its
in vziro and in vivo chemotherapeutic activities against M. tuberculosis (7, 9), although undis-
putable in vivo experimental chemotherapeutic trials have not appeared in literature as far as the
authors concern. A certain degree of cross-resistance between rifabutin and RMP against M.
tuberculosis may indicate limited usefulness in the treatment of RMP-resistant tuberculosis (10).
Enthusiasm has been prevailing, however, in the studies on rifabutin regarding M. avium com-
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plex, in the hope that the treatment regimens may be improved by this agent. In vz"tro superior
antimycobacterial activity of rifabutin to RMP has already been clearly demonstrated, although a
kind of cross-resistance between rifabutin and RMP exists as well for M. avium complex (11).
Twenty disease-associated strains of M. avium complex isolated in our laboratory were de-
monstrated again to be highly susceptible in vz"tro to rifabutin in the present study. Superiority
of rifabutin to RMP WaS undisputably confirmed with the three kinds of media. On Ogawa
medium, however, the strains with higher MICs of RMP were also the strains with higher MICs
of rifabutin. This tendency of parallelism in susceptibility between rifabutin and RMP was
confirmed in a correlation analysis of MICs of both drugs in KB but not in DTA, since the
correlations of MICs were 0.97 (p <0.01, t-test) and 0.27 (N.S.), in KB and DTA, respectively.
It is likely that the relationship between varying levels of resistance to RMP and a concentra-
tion-dependent cross-resistance to rifabutin in KB was disarranged in DTA due to unknown
factors, which probably existed in some ingredients in DTA.
In in vivo study, the total numbers of grossly visible disease in lung of mice demonstrated
marginal superiority of rifabutin to RMP. This superiority, however, was not like the one which
had been expected from in vz"tro activities of rifabutin. The 'discrepancy between in vz"tro and in
vivo studies may be explained from several points of view, although our results are not com-
pletely conclusive and much study should be done in the future.
First, the strain 31F093T (No. 6 in table 1) used in vivo study was partially resistant ot 50
Jig/ml of rifabutin on Ogawa medium. Provided the bioavailability of rifabutin is same as
RMP, this rather high degree of resistance does not appear to allow us to expect potent activity
against human as well as animal infections. In chemotherapy of human M. tuberculosis infec-
tion with RMP, the resistance to 50 Jig/ml on Ogawa medium usually inidcates no or low che-
motherapeutic activity. Four of 10 strains tested on Ogawa medium (table 1) were susceptible to
10 Jig/ml of rifabutin. Therefore, in vivo activity of rifabutin is still to be expected against these
strains. Unfortunately, in animal study (15), high virulence z'n vivo and high degrees of resis-
tance in vitro to drugs including RMP and possibly rifabutin coexist, and, moreover, 31F093T
strain has been only the mouse-virulent strain thus far selected in our laboratory for experimental
chemotherapy of M. avium complex infection.
Second, in a correlation analysis of MICs between rifabutin and RMP in DTA, the corre-
lation coefficient was 0.27 with no significance. although a high correlation (0.97, P < 0.01) was
observed in KB. It is probable that Tween 80® in DTA influenced the permeability of individual
strains with varying degrees, and in vz"tro activity of rifabutin may depend more on these changes
of permeability than RMP. In the present study with DTA, in vitro activity of rifabutin
could have been unduly enhanced in some strains. In this sense, in vz"tro susceptibility test
could be more reliable on KB or Ogawa medium for correlating in vitro and in vivo activities
of rifabutin.
Third, in vIew of the in vitro superiority of rifabutin to RMP even on Ogawa medium,
apparently same potency of rifabutin and RMP in the evaluations of consecutive viable bacilli in
mouse organs is still to be explained. One explanation, although by pure speculation, may be
that: a part of rifabutin could be metabolized to less active metabolites possibly in mouse macro-
phages, and the difference of potency between rifabutin and RMP could be much smaller in
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experimental chemotherapy.
Finally, no dose responses In the present in vivo study of both rifabutin and RMP were be-
yond explanation. Although all the parameters at 12 wks of infection (figure 3, 4, 5) appeared
to demonstrate some favorite responses in the mice treated with highest dose (25 mg/Kg) of ri-
fabutin, the authors thought it as negligible.
One thing is certain that rifabutin suppressed moderately the grossly visible lung diseases of
mice infected with our resistant strain. It is stjl1 encouraging that the addition of rifabutin to
the treatment regimens of M. avium complex infections may prove synergism which could be
valuable for clinical use.
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Minimal Inhibitory Concentration of LM 427 and Rifampin against
20 Mycobacterium avium complex strains
Strain No.
0.05% Tween al bumin
___ liqui~rnedi~~ . _
LM 427 RFP
Kirchner's liquid medium with
__~10% bovine serum
LM 427 RFP
11
12
13
15
17
14
1
6
18
19
3
8
16
9
4
5
2
7
10
20
~O. 00039
~O. 00039
~O. 00039
~O. 00039
~O. 00039
~O. 00039
0.00313
0.00313
0.00313
0.00625
0.0125
0.0125
0.0125
0.0125
0.025
0.05
0.05
0.05
O. 1
O. 1
0.00313
0.00313
O. 1
0.78
1.56
1.56
0.2
0.2
3.13
0.00625
0.78
1.56
1. 56
6.25
0.39
0.78
1.56
3.13
1.56
1. 56
0.00156
0.0125
0.05
6.25
6.25
6.25
1.56
0.05
6.25
0.025
3.13
1.56
6.25
1. 56
0.39
0.78
6.25
6.25
0.0125
1. 56
0.1
3.13
25.0
100.0
100.0<
100.0
50.0
1. 56
100.0
1. 56
50.0
50.0
100.0
50.0
12.5
12.5
100.0
100.0
25.0
25.0
'----v----'
r=O. 27 (N.S.)
'----v----'
r=0.97 (p<O.OOOl)
